Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HaloVax
- Development stage
- Preclinical
- Lead developer
- Voltron Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Intravenous
01
Overview
HaloVax is a proprietary bio-nanoparticle delivery platform and vaccine candidate series developed by Halo-Bio RNAi Therapeutics. The technology utilizes gas vesicles (GVs) derived from the haloarchaeon *Halobacterium salinarum*. These GVs are naturally occurring, hollow, proteinaceous structures that are highly stable and can be engineered to display antigens on their surface or encapsulate therapeutic payloads such as small interfering RNA (siRNA) or short hairpin RNA (shRNA). The platform is designed for oral or systemic delivery, leveraging the inherent stability of GVs to protect payloads from degradation in the gastrointestinal tract or bloodstream. Primary research areas include oncology, where the platform is used to deliver RNAi targeting specific oncogenes, and infectious diseases, such as COVID-19, where the GVs serve as both a delivery vehicle for viral antigens and a potential self-adjuvanting system.
- Brand names
- HaloVax
- Other names
- Halo-Bio vaccineHalobacterium gas vesicle vaccine
Beyond the preview
Go deeper on HaloVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HaloVax.